TrialGynecologic oncology2020

Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002).

Alessandro D Santin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.